Muscular Dystrophy Association, Inc.

https://mda.org

The Muscular Dystrophy Association (MDA) is the leading voluntary health organization in the United States dedicated to the fight against muscular dystrophy, amyotrophic lateral sclerosis (ALS), and over 300 other neuromuscular conditions. Established in 1950, its core mission is to empower individuals affected by these diseases to live longer, more independent lives by accelerating research, advancing care, and advocating for support and inclusion. The organization's headquarters are located in Chicago, Illinois.

MDA provides a comprehensive range of services and programs, including funding innovative research to develop treatments and cures, and offering access to expert medical care through its extensive Care Center Network, which comprises over 150 clinics nationwide. The association also delivers vital resources, such as its Resource Center, summer camps for children, support groups, equipment assistance, and advocacy initiatives. Through its Quest Media platform, MDA publishes a quarterly magazine, podcast, and blog, fostering a supportive community and providing educational content for patients and caregivers.

Under the leadership of President and CEO Sharon Hesterlee, PhD, who was appointed in November 2025, MDA continues to drive progress in the neuromuscular disease community. Recent activities include marking May as ALS Awareness Month to highlight scientific advancements, personal stories, and legislative advocacy. The organization also engages in significant fundraising efforts, such as the annual MDA Wings Over Wall Street Gala and partnerships with entities like the International Association of Fire Fighters for the "Fill the Boot" campaign and Burn Boot Camp for the "Be Their Muscle" campaign. MDA has also been instrumental in advocating for legislation like the Accelerating Access to Critical Therapies for ALS Act and invests in promising companies developing novel therapies for neuromuscular diseases.

Latest updates

MDA Highlights ALS Research Advances, Advocacy Push Amidst Growing Patient Needs

Event summary

  • The Muscular Dystrophy Association (MDA) is focusing on ALS research and advocacy during May, designated ALS Awareness Month.
  • Researchers at NIH, led by Dr. Bryan Traynor, have identified a potential blood test for early ALS detection and are exploring drug repurposing strategies.
  • MDA has awarded nearly $2 million in ALS grants in 2025 and invested over $180 million in research to date.
  • MDA is advocating for the reauthorization of the ACT for ALS and passage of the ALS Better Care Act to expand access to care and improve quality of life.
  • Richard Govoni left a legacy gift of over $300,000 to MDA to advance ALS research, inspiring others to contribute.

The big picture

The MDA’s focus on ALS research and advocacy reflects a broader trend in neurodegenerative disease treatment – a shift from symptom management to early detection and targeted therapies. The organization's significant investment ($180M+) and partnerships underscore the growing recognition of ALS as a complex and urgent public health challenge. The emphasis on legislative advocacy highlights the critical role of policy in enabling research and improving patient access to care.

What we're watching

Legislative Risk
The reauthorization of the ACT for ALS and passage of the ALS Better Care Act are crucial for patient access and funding; failure to secure these could significantly impact care and research progress.
Diagnostic Adoption
The investigational blood test’s accuracy and regulatory approval will determine its adoption rate and impact on early diagnosis, potentially shifting clinical trial enrollment patterns.
Fundraising Sustainability
MDA’s reliance on fundraising campaigns, like the Fill the Boot and Dutch Bros initiatives, highlights the need to maintain donor engagement to sustain research and care programs.

Burn Boot Camp's Decade-Long Partnership Drives $3.8M for Muscular Dystrophy Association

Event summary

  • Burn Boot Camp and the Muscular Dystrophy Association (MDA) are celebrating the 10th annual ‘Be Their Muscle’ campaign in April 2026.
  • The partnership has raised over $3.8 million since 2016 through fundraising and workout proceeds.
  • Funds support MDA’s research, care, advocacy, and summer camp programs for individuals with neuromuscular diseases.
  • Burn Boot Camp operates over 400 locations and has awarded over 620 territories nationwide.
  • MDA National Ambassador Lily Sander, who lives with Charcot-Marie-Tooth disease, expressed gratitude for the campaign's support.

The big picture

This decade-long partnership highlights a growing trend of fitness brands aligning with charitable causes to enhance brand image and engage communities. Burn Boot Camp's franchise model provides a scalable platform for fundraising, but also introduces dependencies on franchisee participation. The $3.8 million raised underscores the potential for corporate philanthropy to significantly impact non-profit organizations focused on rare diseases, but also emphasizes the need for sustainable funding models beyond short-term campaigns.

What we're watching

Franchise Sustainability
The continued reliance on Burn Boot Camp’s franchise model for fundraising exposes MDA to risks associated with franchise performance and potential shifts in consumer fitness trends.
Donor Retention
MDA's ability to sustain fundraising levels will depend on maintaining engagement within the Burn Boot Camp community and attracting new donors beyond the initial decade of support.
Programmatic Impact
The effectiveness of MDA's programs, particularly research initiatives, will be under scrutiny as funding increases; demonstrating tangible outcomes will be crucial for justifying continued support.

Spinraza Dosing Regimen Approved, Highlighting Decades of MDA-Funded Research

Event summary

  • The FDA approved a high-dose regimen of SPINRAZA® (nusinersen) for the treatment of spinal muscular atrophy (SMA).
  • The new regimen is based on findings from the DEVOTE study and aims to deliver a higher concentration of the drug.
  • MDA has invested over $1.2 billion in research, including $50 million in SMA research, contributing to the development of SPINRAZA.
  • Dr. Adrian Krainer’s lab at Cold Spring Harbor Laboratory, supported by MDA funding, pioneered the antisense oligonucleotide approach used in SPINRAZA.

The big picture

The FDA approval underscores the long-term value of sustained research investment in rare diseases, demonstrating how foundational funding from organizations like MDA can translate into commercially viable therapies decades later. This approval also highlights the ongoing evolution of treatment paradigms, with dosage optimization becoming a key area of innovation in established therapies. The success of SPINRAZA and the new high-dose regimen reinforces the importance of patient advocacy and community involvement in driving medical progress.

What we're watching

Clinical Efficacy
The real-world clinical impact of the high-dose regimen will need to be closely monitored, particularly regarding sustained benefits and any unforeseen long-term effects beyond the DEVOTE study data.
Market Dynamics
The approval could shift market share within the SMA treatment landscape, potentially impacting competitors and influencing pricing strategies for existing therapies.
Funding Model
The continued reliance on non-profit organizations like MDA for early-stage research funding highlights the ongoing need for alternative funding models in drug development, particularly for rare diseases.

Neuromuscular Therapies Advance as MDA Conference Highlights Gene Editing and Regulatory Shifts

Event summary

  • The 2026 MDA Clinical & Scientific Conference convened over 2,400 attendees from 40 countries in Orlando, Florida.
  • Keynote speaker John Crowley emphasized the role of patient-driven innovation and cross-sector collaboration in rare disease treatment.
  • FDA Associate Director Amy Comstock Rick highlighted the agency’s Rare Disease Innovation Hub and efforts to accelerate therapy development.
  • The conference recognized Łukasz Sznajder with the inaugural MDA Research Momentum Award for his work on neuromuscular disorders.

The big picture

The conference underscores a pivotal moment in neuromuscular medicine, where scientific breakthroughs are increasingly translating into tangible therapies. This acceleration is fueled by advancements in gene editing and RNA-targeted therapies, alongside a more proactive regulatory environment. The MDA's convening power is vital for ensuring equitable access and driving further innovation within a market increasingly focused on rare disease treatments.

What we're watching

Regulatory Headwinds
The FDA’s continued focus on streamlining rare disease drug approvals could accelerate market entry, but also increase scrutiny of efficacy and safety data, potentially impacting smaller biotech firms.
Collaboration Dynamics
MDA’s role as a convener will be crucial in navigating the complex landscape of research, clinical care, and industry partnerships, particularly as gene therapies become more prevalent.
Execution Risk
The rapid translation of scientific discovery to bedside therapies carries inherent execution risk; monitoring clinical trial outcomes and manufacturing scalability will be critical for sustained progress.

MDA's Shamrock Campaign Drives $400M in Neuromuscular Disease Support

Event summary

  • The Muscular Dystrophy Association (MDA) launched its annual MDA Shamrocks campaign on February 18, 2026.
  • The campaign has raised nearly $400 million over 44 years, contributing to over 30 FDA-approved treatments for neuromuscular conditions in the last decade.
  • Retail partners across the country are participating, offering customers options to donate or round up purchases.
  • A limited-edition T-shirt designed by MDA Board member Matthew Plummer is available for online donations of $45 or more.

The big picture

The MDA Shamrocks campaign exemplifies the power of long-term, community-driven fundraising in the healthcare sector. The $400 million raised over four decades demonstrates a sustained commitment to neuromuscular disease research and patient support. This model, blending retail partnerships with targeted online initiatives, could serve as a template for other non-profits seeking to build durable fundraising programs, particularly as traditional grant funding faces increasing competition.

What we're watching

Retail Dependence
The MDA's reliance on retail partnerships for fundraising highlights a potential vulnerability; shifts in retail landscape or partner priorities could significantly impact revenue.
Treatment Impact
Continued FDA approvals linked to MDA-funded research will be crucial for maintaining donor engagement and justifying the campaign's ongoing scale.
Online Growth
The success of the online fundraising component, particularly the T-shirt incentive, will determine the viability of expanding digital engagement beyond the traditional retail model.

MDA Award Signals Shift to Early-Stage Neuromuscular Research Investment

Event summary

  • The Muscular Dystrophy Association (MDA) has created the 'MDA Research Momentum Award' to recognize early-career neuromuscular disease researchers.
  • Łukasz Sznajder, PhD, MSc, from the University of Nevada, Las Vegas (UNLV), is the inaugural recipient.
  • The award is linked to the 2026 MDA Clinical & Scientific Conference in Orlando, Florida, March 8–11.
  • The conference typically draws over 2,500 attendees from 41 countries.
  • Sznajder's research focuses on molecular genetics related to neuromuscular and neuropsychiatric disorders, including ALS and myotonic dystrophy.

The big picture

The MDA's creation of the Research Momentum Award signals a deliberate effort to shape the future of neuromuscular disease research by investing in emerging talent. This contrasts with traditional funding models that often prioritize established researchers and institutions. The award's focus on early-career scientists could accelerate innovation and potentially disrupt the existing research landscape, but also carries inherent execution risk given the unpredictable nature of early-stage research.

What we're watching

Funding Focus
The MDA's shift to early-career researchers suggests a strategic move to influence the direction of neuromuscular disease research, potentially impacting established labs and funding priorities.
Research Trajectory
Whether Dr. Sznajder's work, now highlighted by the award, can translate into tangible therapeutic advances will be a key indicator of the award's effectiveness and MDA's investment strategy.
Collaboration
The emphasis on collaboration and mentorship within the award criteria will reveal the extent to which the MDA is fostering a more integrated research ecosystem within the neuromuscular disease field.

Congress Approves $48.7B NIH Funding, Bolsters Rare Disease Programs

Event summary

  • A bipartisan Congressional funding bill was passed, allocating $48.7 billion to the NIH, a 1% increase.
  • $90 million was earmarked for the ACT for ALS program, ensuring its continued implementation.
  • The Accelerating Kids’ Access to Care Act was passed, addressing barriers to specialty care for children with rare conditions.
  • The Rare Pediatric Disease Priority Review Voucher Program was reauthorized, incentivizing therapies for rare pediatric neuromuscular diseases.
  • MDA estimates over 30 FDA-approved treatments have resulted from past research and advocacy efforts in the last decade.

The big picture

This funding package underscores the growing political recognition of the unmet needs within the rare disease space, a sector increasingly attractive to pharmaceutical companies seeking niche markets. The bipartisan nature of the legislation suggests a degree of stability, but future funding cycles remain subject to political dynamics. The continued support for the RPD PRV program signals a commitment to incentivizing drug development for conditions that have historically been neglected, potentially reshaping the therapeutic landscape for these diseases.

What we're watching

Implementation
The effectiveness of the allocated funding will depend on how efficiently NIH and related agencies implement the new programs and policy changes.
Political Risk
Future legislative sessions could see shifts in priorities, potentially impacting the long-term stability of these funding streams and policy provisions.
Innovation Pace
The reauthorization of the RPD PRV program will influence the rate of therapeutic development for rare pediatric neuromuscular diseases, but the actual impact will depend on industry response.

Muscular Dystrophy Research Collaboration Aims to Decipher Human Tissue Regeneration

Event summary

  • The Muscular Dystrophy Association (MDA) has awarded $213,446 to Abigail Mackey, PhD, of Copenhagen University Hospital, to map human muscle regeneration.
  • The research project will compare muscle tissue from healthy individuals with those affected by Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and limb-girdle muscular dystrophy 2L (LGMD2L).
  • The collaboration arose from the MDA Muscle Regeneration Summit held in Quebec, Canada, in July 2024.
  • The data generated will be a shared resource for researchers globally, aiming to accelerate muscle-repair-based therapies.
  • The initiative represents a shift towards human-centered data, moving away from reliance on mouse models in neuromuscular disease research.

The big picture

The collaboration highlights a growing recognition within the neuromuscular disease research field that mouse models are inadequate for understanding human muscle repair. This shift towards human-based data is essential for developing targeted therapies, but requires significant investment and a commitment to data sharing. The initiative's success could unlock new avenues for treating a range of debilitating conditions affecting millions globally.

What we're watching

Data Accessibility
The success of this initiative hinges on the open accessibility and standardization of the generated data, which will determine its impact on broader research efforts.
Clinical Translation
The ability to translate the detailed molecular understanding of muscle regeneration into tangible therapeutic interventions will be a key indicator of long-term value.
Funding Sustainability
Continued funding from MDA and its partners will be crucial to sustain the project and expand its scope to encompass a wider range of neuromuscular diseases.

MDA Highlights Community Impact as Rare Disease Research Lags

Event summary

  • The Muscular Dystrophy Association (MDA) is spotlighting community stories to mark Rare Disease Day on February 28, 2026.
  • MDA estimates that 7,000 to 10,000 rare diseases affect 25 to 30 million people in the United States, most lacking effective treatments.
  • MDA has operated for 75 years, funding research, providing care through MDA Care Centers, and advocating for individuals with neuromuscular diseases.
  • MDA’s programs include the Resource Center and Gene Therapy Support Network, offering guidance on diagnosis, clinical trials, and caregiving.

The big picture

The MDA’s focus on community stories underscores a persistent challenge in the rare disease space: the lack of effective treatments and the fragmented nature of care. While patient advocacy groups play a vital role, the sheer number of rare diseases (7,000-10,000) and the limited resources available for research and development create a significant hurdle. MDA’s 75-year history demonstrates a commitment to bridging this gap, but sustained progress requires a coordinated effort involving researchers, clinicians, policymakers, and patient communities.

What we're watching

Funding Sustainability
MDA’s reliance on donations and grants makes its long-term operational stability contingent on continued fundraising success, particularly given the broad scope of diseases it supports.
Research Translation
The stories highlight the need for research to translate into tangible therapies; MDA’s ability to influence clinical trial participation and outcomes will be a key indicator of its impact.
Advocacy Effectiveness
The organization’s advocacy efforts will need to demonstrate a clear impact on policy and resource allocation to address the systemic challenges faced by individuals with rare neuromuscular diseases.

Neuromuscular Research Gains Momentum as MDA Honors Key Innovators

Event summary

  • The Muscular Dystrophy Association (MDA) awarded its 2026 Legacy Awards to Michio Hirano (clinical research) and Allison Moore (community impact) on January 14, 2026.
  • The awards recognize contributions to neuromuscular and mitochondrial disorder research and advocacy, respectively.
  • The 2026 MDA Clinical & Scientific Conference will be held in Orlando, Florida, on March 9, 2026.
  • MDA renamed the Community Impact Award in honor of Donavon Decker, who passed away in September 2025, following his pioneering gene therapy work.
  • MDA will announce the inaugural Research Momentum Award in February 2026, recognizing early-career investigators.

The big picture

The MDA’s recognition of both scientific advancement and community leadership underscores the growing importance of patient advocacy and collaborative research in addressing rare diseases. The renaming of the Community Impact Award in honor of Donavon Decker highlights the increasing role of patient experience in driving innovation and shaping the therapeutic landscape for neuromuscular disorders. This event signals a broader trend toward patient-centricity within the biotechnology sector, where understanding and addressing patient needs is becoming a key differentiator.

What we're watching

Award Impact
The visibility afforded by the MDA Legacy Awards could accelerate the adoption of Dr. Hirano’s and Moore’s approaches within the broader research community, potentially influencing future funding decisions.
Research Momentum
The introduction of the Research Momentum Award signals MDA’s intent to cultivate the next generation of neuromuscular disease researchers; the selection criteria will reveal MDA’s strategic priorities.
Patient Voice
The emphasis on patient-centered research and Allison Moore’s leadership suggests a continued push for greater patient involvement in clinical trial design and therapeutic development, which may impact trial timelines and outcomes.
CID: 489